CTRI/2021/08/035665尚未招募4 期
A prospective, open-label, multicentre, randomized, non-inferiority clinical trial to compare the safety and performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System versus Contemporary DES platforms in patients with de novo coronary artery lesions. - MeRes100ââ??¢ Sirolimus-eluting BRS
Meril Life Sciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •General Inclusion Criteria:
- •1.Male or female patient ââ?°Â¥18 years of age
- •2.Subject who has provided written informed consent
- •3.Subject must agree to undergo all clinical investigations and follow-up visits as per protocol
- •4.Subject with documented myocardial ischemia (e.g., stable, unstable angina, or silent ischemia) and who are eligible candidates for elective percutaneous coronary intervention (PCI)
- •5.Subject must agree not to participate in any other clinical trial for a period of one year following the index procedure. This includes clinical trials of medications and/or invasive procedures. Questionnaire-based studies, or other studies that are non-invasive and do not require medication are allowed
- •Angiographic Inclusion Criteria:
- •1.One de novo target lesion or up-to two de novo target lesions in different epicardial vessels: Different epicardial vessels are defined as left anterior descending artery (LAD) and its branches, left circumflex artery (LCX) arteries and its branches, and right coronary arteries (RCA) and its branches. Thus, for example, the subject must not have two target lesions required to be treated at the LAD and its branches at the same time
- •2.Each target lesion can be fully covered by one scaffold
- •3.Target lesion with angiographic evidence of ââ?°Â¥70% stenosis (by visual estimation) and ââ?°Â¥50% (by QCA estimation) with TIMI flow of ââ?°Â¥1. If the target lesion is <70% stenosed, there must be an evidence of ischemia as per ECG or nuclear scan or fractional flow reserve (FFR)
- •4.Target lesion(s) located in native coronary artery with reference vessel diameter (RVD) of ââ?°Â¥2.75 mm to ââ?°Â¤4.0 mm and length ââ?°Â¤34 mm by QCA or by visual estimation
排除标准
- •General Exclusion Criteria:
- •1.Known hypersensitivity or contraindication to aspirin, both heparin and
- •bivalirudin, antiplatelet medication specified for use in the study (clopidogrel, prasugrel, ticlopidine inclusive), everolimus, sirolimus or its analog or derivative, poly (L-lactide), poly (DL-lactide), cobalt, PLGA [poly(DL-lactide-co-glycolide)], chromium, nickel, tungsten, stainless steel, platinum, platinum-chromium alloy, iron, molybdenum, amorphous silicon carbide, acrylic and fluoropolymers or contrast sensitivity that cannot be adequately pre-medicated
- •2.Any PCI <6 months prior to the index procedure
- •3.Previous CABG or PCI in the target vessel(s)
- •4.Left ventricular ejection fraction (LVEF) <30% as evaluated by any non-invasive imaging method including but not limited to, echocardiogram, angiography, Magnetic Resonance Imaging (MRI), Multiple-Gated Acquisition (MUGA) scan, radionuclide ventriculography, Positron Emission Tomography (PET) scan, etc. For subjects with stable Coronary Artery Disease (CAD), LVEF may be obtained within 6 months prior to the procedure. For Acute coronary syndrome (ACS) subjects, LVEF must be
- •evaluated during hospitalization or during index procedure but prior to randomization for confirming the subjectââ?¬•s eligibility
- •5.Concurrent medical condition with less than three years of life expectancy
- •6.Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months of baseline visit
- •7.Renal insufficiency as estimated by Glomerular Filtration Rate (GFR) <30 ml/min/1.73m2 or dialysis at the time of screening or creatinine level is more than 1.5 mg/dl
- •8.Subject with cardiac arrhythmia detected at the time of screening
- •9.Subject is on immunosuppressant therapy and has immunosuppressive or autoimmune disease
- •10.Subject with hepatic disorder or chronic liver disease, known aplastic anaemia, platelet count <100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3
- •11.Subject with prior brachytherapy of the target lesion or use of
- •brachytherapy for the treated site restenosis
- •12.Subject has a history of bleeding diathesis or coagulatory disease, refuses
- •blood transfusion, significant gastrointestinal or urinary bleed within the past 12 months
- •13.Subject who underwent or needs organ transplant
- •14.Planned PCI for any clinically significant lesion after index procedure
- •15.Planned surgery within 12 months after index procedure
- •16.Pregnant or nursing subject and those who plan pregnancy in the period until 5 years following index procedure (Female subject of child-bearing potential must have a negative pregnancy test done within 7 days prior to
- •the index procedure and contraception must be used during participation in this trial)
- •17.Any newly onset acute myocardial infarction within 1 week ( <7days) or, myocardial enzyme has not returned to normal level (clinically non-significant) after myocardial infarction
- •18.Subject with significant peripheral vascular disease that precludes safe access to sheath or catheter
- •Angiographic Exclusion Criteria:
- •1.Target lesion located within 3 mm of the origin of the LAD or LCx
- •2.Target lesion involving a bifurcation lesion with side branch ââ?°Â¥2 mm in diameter
- •3.Highly calcified lesions <
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-ESAB Science75
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or Best suportiv care) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 19.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-CZAB Science150
进行中（未招募）
1 期
Evaluation of masitinib combined to gemcitabine, carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer relapsing after a first chemotherapy treatmentMetastatic or locally advanced breast cancerMedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864EUCTR2010-022646-24-ESAB Science60
进行中（未招募）
不适用
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or Best Supportive Care) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 18.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-GRAB Science120
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesEUCTR2013-000493-30-SKAB Science150